Skip to content
Search

Latest Stories

Submit Guest Post

Uber teams up with Arrival to make electric ride-hailing car

UBER has teamed up with UK technology startup Arrival to create an electric car for the app-based US ride-hailing firm that will help to cut emissions, the pair said Tuesday (4).

The vehicle is expected to enter production in the third quarter of 2023 and the two companies will "explore a strategic relationship in key markets, including the UK and EU", according to a statement.


It comes after six-year-old Arrival, which is creating also electric vans and buses, listed on Wall Street's Nasdaq in March.

"Arrival, the global technology company creating electric vehicles using its game-changing technologies, is partnering with Uber to develop an affordable, purpose-built electric vehicle for ride-hailing drivers," the statement said.

The Arrival car "will address the global need to shift ride-hailing and car sharing services... to electric to reduce emissions and improve air quality in cities", it added.

Uber has committed to becoming a fully-electric mobility platform in London by 2025 and by 2030 across North America and Europe, the statement noted.

"As our cities open up we have an opportunity to make sure that urban transport is cleaner than ever before," said Jamie Heywood, Uber's regional general manager for Northern and Eastern Europe.

The car "will be designed around drivers' needs to create a vehicle that is affordable, durable and desirable", said Tom Elvidge, senior vice president Arrival Mobility UK.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

AstraZeneca

AstraZeneca chief executive Pascal Soriot says the company has the science, pipeline and team to deliver its long-term growth ambitions

Getty Images

AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment

  • AstraZeneca expects its restructuring programme to generate $1.5bn in annualised savings by 2029, with most of the money reinvested in research and development.
  • The plan could incur up to $2bn in one-off restructuring costs, although the company expects its overall workforce to continue growing.
  • Third-quarter revenue rose 7 per cent to $16.21bn, while oncology sales increased 17 per cent to $7.77bn.

AstraZeneca has unveiled plans to generate around $1.5bn in annual savings through a three-year restructuring programme, as chief executive Pascal Soriot shifts the focus back to growth and investment in its drug pipeline.

The British-based pharmaceutical group said its Reshaping for Sustainable Growth programme would redirect resources towards research and development, particularly its pipeline of more than 180 projects and emerging technologies.

Keep ReadingShow less